← Back

$ Value

Shares

1,500

Price

Filed

Feb 26

Insider

Name

Hopper Jonathan Mark

Title

Chief Medical Officer

CIK

0001626325

Roles

Officer

Transaction Details

Transaction Date

2026-02-24

Code

M

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

6,000

Footnotes

The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. | The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 20, 2025, the Reporting Person deferred the receipt of 350 shares of Common Stock and instead received 350 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. | These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). | The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. | These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. | The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. | The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. | Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. | No expiration date for this type of award. | The Fair Market Value of the vested derivative securities is $38.09 per share. | The Fair Market Value of the vested derivative securities is $38.25 per share.

Filing Info

Accession No.

0001140361-26-006973

Form Type

4

Issuer CIK

0000887359

Hopper Jonathan Mark's History

Date Ticker Type Value
2026-04-02 VCEL M $38K
2026-04-02 VCEL $122K
2026-04-02 VCEL M $0
2026-02-24 VCEL M
2026-02-24 VCEL M $0
2026-02-24 VCEL F $51K
2026-02-24 VCEL M
2026-02-24 VCEL M $0
2026-02-24 VCEL F $24K
2026-02-24 VCEL M

Other Insiders at VCEL (90d)

Insider Bought Sold Last
MCLAUGHLIN KEVIN F $243K 2026-02-11
Colangelo Dominick
President and CEO
2026-02-24
Rubino Alan L 2026-03-25
Hagen Heidi $486K 2026-03-23
Hopper Jonathan Mark
Chief Medical Officer
$122K 2026-04-02
Halpin Michael
Chief Operating Officer
$364K 2026-03-02
Flynn Sean C.
Chief Legal Officer
$754K 2026-03-02
Mara Joseph Anthony Jr
Chief Financial Officer
2026-02-24
SIEGAL JONATHAN
Principal Accounting Officer
2026-02-24